However, in the CNS, the KIF3C peptide can efficiently induce glioma-reactive cytotoxic T lymphocytes (CTLs) from patients, indicating an effective peptide-based immunotherapy for glioma patients [31]. This evidence concerns the gene KIF3C and central nervous system cancer.